HALEOS LABS LIMITED
HALEOS LABS LIMITED is an Indian listed company in the Pharmaceuticals & Biotechnology industry (Healthcare sector), traded under NSE: HALEOSLABS and BSE: 540679 (ISIN INE320X01016).
It has a market capitalisation of ₹465 crore, a last close of ₹1,538 on 2026-10-19, a one-year return of 36.5%.
Valuation: a price-to-earnings ratio of 29.43x, a price-to-book ratio of 2.18x, a dividend yield of 0.1%.
Profitability: return on equity of 8.4%, return on capital employed of 11.6%, an operating margin of 12.6%.
Growth: sales growth of 1.9% a year over three years, net profit growth of 14.7% a year over three years.
Balance sheet and ownership: debt-to-equity of 0.51x, promoter holding of 72.1%.
| Metric | Value |
|---|---|
| Market capitalisation | 465 |
| Last close | ₹1,538 |
| P/E (TTM) | 29.43x |
| P/B | 2.18x |
| Dividend yield | 0.1% |
| ROE (FY) | 8.4% |
| ROCE (FY) | 11.6% |
| Operating margin (TTM) | 12.6% |
| Sales growth, 3-year CAGR | 1.9% |
| Profit growth, 3-year CAGR | 14.7% |
| Debt / equity | 0.51x |
| Promoter holding | 72.1% |
| 1-year return | 36.5% |
Loading the live page with the price chart, financial history, shareholding and recent filings. Data is end-of-day and rebuilt nightly; nothing here is investment advice. Financial statements · What each metric means